PANACEABIO — Panacea Biotec Income Statement
0.000.00%
- IN₹25.15bn
- IN₹23.54bn
- IN₹5.59bn
- 33
- 13
- 79
- 35
Annual income statement for Panacea Biotec, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6,248 | 6,612 | 4,599 | 5,592 | 5,591 |
Cost of Revenue | |||||
Gross Profit | 3,653 | 3,234 | 1,492 | 2,545 | 3,596 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 5,894 | -9,608 | 4,657 | 5,728 | 5,838 |
Operating Profit | 354 | 16,220 | -57.5 | -137 | -247 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1,442 | 14,488 | 128 | 14.8 | -79.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,462 | 10,779 | -337 | -15.1 | -87.2 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -1,477 | 10,779 | -332 | -11.7 | -83.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1,477 | 10,779 | -332 | -11.7 | -83.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -23.4 | -1.82 | -16.5 | -3.53 | -5.2 |